Vivanza Biosciences Limited (VIVANZA)

BSE: ₹1.80
Stock Performance
Corporate Announcements
Board Meeting Intimation for Intimation Of The Meeting Of The Board Of Directors Pursuant To Regulations 29 And 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

1.To authorise Mr. Sarang Bharatbhai Pathak (DIN: 02663344) to sign the Financial Statements for the financial year ended 31st March 2026 on behalf of the Board 2.To take note of the consent received from M/s. Dharti Shah & Co. and appoint it as an Internal Auditor of the Company for the Financial Year 2026-2027. 3.To consider and approve the appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director of the Company. 4. To consider and approve the transfer of certain unverified shares to the Unclaimed Suspense Account pending verification of the identity and entitlement of the rightful shareholders and to authorize the Registrar and Share Transfer Agent to process and release such shares from the Unclaimed Suspense Account upon receipt and verification of the prescribed KYC and other supporting documents, subject to confirmation by the Company and applicable laws.

2026-06-15 11:43:37
Announcement under Regulation 30 (LODR)-Newspaper Publication

In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region, where the registered office of the Company is situated for extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended on March 31st, 2026

2026-05-09 11:56:03
Non Applicability Of Related Party Transaction Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015 For The Quarter And Year Ended 31St March, 2026

This is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations, 2015, Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations, 2015 shall not apply to listed entities having paid up equity share capital not exceeding Rupees 10 crores and net worth not exceeding Rupees 25 crores as on the last day of previous financial year. The paid-up equity share capital and net worth of the Company as on 31st March, 2025 are Rs. 4,00,00,000 and Rs. 4,02,03,752.40 respectively

2026-05-07 23:16:32
Results- Quarterly And Year To End Dated 31St March 2026

Audited Standalone Financial Results for the Quarter and Year ended on 31st March, 2026, Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS, Reconstitution of Committees of the Board

2026-05-07 23:09:02
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended On 31St March, 2026

Consideration of Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Audit Report of the Company for the Quarter and Year ended 31st March, 2026, Took note of the Resignation of Mr. Hemant Amrish Parikh as a Non-Executive Director of the Company, Took note of the Resignation of CS Chaitra Arora from the position of the CS and compliance officer, Reconstitution of Committees of the Board with effect from 07th May, 2026

2026-05-07 22:58:11
Board Meeting Intimation for Rescheduling Of Board Meeting-Intimation Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

This is in continuation of our earlier intimation dated April 28, 2026, regarding the Board Meeting scheduled on May 4, 2026, to consider and approve the audited standalone and consolidated financial results along with the Audit Report for the quarter and year ended March 31, 2026. Due to unavoidable circumstances, the meeting has been rescheduled to May 7, 2026, to consider the same agenda. Further, the trading window shall remain closed until 48 hours after the declaration of the said financial results, in accordance with the Company’s Code of Conduct for Prevention of Insider Trading.

2026-05-04 15:09:42
Announcement under Regulation 30 (LODR)-Change in Management

Intimation Regarding Resignation of Company Secretary & Compliance Officer pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015.

2026-04-30 16:09:59
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

Intimation regarding Resignation of Company Secretary & Compliance Officer pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015.

2026-04-30 16:05:28
Board Meeting Intimation for Board Meeting Intimation For Intimation Under Regulation 29(1)(A) And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Vivanza Biosciences Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/05/2026 ,inter alia, to consider and approve 1. Audited Standalone and Consolidated Results along with Audit Report for the Quarter and Year ended 31st March, 2026; 2. Any other business with the permission of Chairman.

2026-04-28 14:24:46
Compliances-Reg.24(A)-Annual Secretarial Compliance

Non-Applicability of Regulation 24A of SEBI(LODR) Regulations, 2015

2026-04-15 12:12:39

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 4.88 3.87 3.37 2.30 0.43 1.58 0.76 0.17 7.82 53.73 44.93 5.75
YOY Revenue Growth % 108.02% 271.31% -29.89% -61.81% -91.23% -59.11% -77.36% -92.62% 1728.1% 3293.66% 5795.89% 3287.97%
Other Income 0.01 0.05 0.02 -0.03 0.00 0.00 0.01 0.02 0.02 0.01 0.08 0.01
Total Income 4.89 3.92 3.38 2.27 0.43 1.59 0.77 0.19 7.84 53.74 45.01 5.75
Total Expenses + 4.56 3.74 3.20 2.54 0.20 1.58 0.73 1.15 7.82 53.28 44.85 5.88
Cost of Materials Consumed 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Employee Benefit Expense 0.08 0.08 0.08 0.07 0.09 0.09 0.07 0.11 0.09 0.16 0.04 0.04
Other Expenses 0.08 0.04 0.11 0.09 0.10 0.02 0.11 0.09 0.09 0.04 0.09 0.00
Operating Profit 0.31 0.13 0.16 -0.24 0.22 0.00 0.03 -0.98 0.00 0.45 0.08 -0.13
OPM % 6.4% 3.5% 4.9% -10.3% 52.2% 0.2% 3.7% -579.8% 0% 0.8% 0.2% -2.3%
Profit Before Tax + 0.33 0.19 0.18 -0.27 0.23 0.01 0.04 -0.96 0.02 0.46 0.16 -0.12
Tax Expense 0.00 0.00 0.00 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.14
Tax % 0% 0% 0% - 0% 0% 0% - 0% 0% 0% -
Profit After Tax 0.33 0.19 0.18 -0.38 0.23 0.01 0.04 -0.97 0.02 0.46 0.16 -0.27
EPS (Basic) 0.01 0.05 0.01 -0.09 0.06 0.00 0.01 -0.24 0.01 0.12 0.04 -0.07

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 112.23 2.94 14.41 14.21 9.15 9.22
YOY Revenue Growth % 3713.75% -79.58% 1.45% 55.31% -0.82% -
Other Income 0.11 0.03 0.05 0.39 0.83 0.50
Total Income 112.34 2.98 14.47 14.59 9.98 9.72
Total Expenses + 111.82 3.67 14.04 13.91 9.51 9.58
Employee Benefit Expense 0.33 0.37 0.31 0.26 0.12 0.29
Other Expenses 0.22 0.31 0.32 0.27 0.50 0.24
Operating Profit 0.41 -0.73 0.37 0.30 -0.36 -0.35
OPM % 0.4% -24.7% 2.6% 2.1% -4% -3.8%
Profit Before Exceptional 0.52 -0.69 0.43 0.69 0.46 0.15
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 0.52 -0.69 0.43 0.69 0.46 0.15
Tax Expense 0.14 0.00 0.11 0.12 0.00 0.05
Tax % 27.6% - 26% 17.2% 0.1% 32.5%
Profit After Tax 0.37 -0.70 0.32 0.57 0.46 0.10
EPS (Basic) 0.09 -0.17 0.08 1.42 1.16 0.25

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 2.63 2.53 2.54 2.51 2.51 2.52
Property, Plant & Equipment 0.12 0.02 0.03 0.00 0.00 0.01
Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.00
Non-Current Investments 1.91 1.91 0.00 1.91 0.00 1.91
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.00 0.00 0.00 0.00 0.00 0.00
Current Assets + 15.59 11.38 14.33 17.93 8.96 5.41
Inventories 2.95 1.84 1.80 1.61 2.23 0.40
Trade Receivables 10.66 7.39 10.37 12.18 7.35 6.11
Cash and Cash Equivalents 0.02 0.05 0.09 0.10 -2.72 -3.11
Current Investments 0.00 0.00 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity 4.40 4.02 4.72 4.40 3.83 3.37
Equity Share Capital 4.00 4.00 4.00 4.00 4.00 4.00
Other Equity 0.40 0.02 0.72 0.40 -0.17 -0.63
Non-Current Liabilities 0.88 0.78 0.78 0.00 7.64 0.00
Current Liabilities 12.95 9.12 11.38 16.04 0.00 4.57
Total Liabilities 13.83 9.89 12.16 16.04 7.64 4.57

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities -1.21 -2.47 1.80 0.16 -0.68 -0.75
Cash from Investing Activities 0.05 -0.01 -0.04 0.00 0.00 -0.02
Cash from Financing Activities 1.13 2.44 -1.77 -0.08 1.07 0.47
Net Increase/Decrease in Cash -0.03 -0.04 -0.01 0.09 -2.72 -0.30